-+ 0.00%
-+ 0.00%
-+ 0.00%

Innate Pharma Highlights Continued Oncology Advancements at ASCO 2025 With Lacutamab, IPH4502, And AstraZeneca's NeoCOAST-2 Data

Benzinga·05/19/2025 06:37:30
Listen to the news
  • Long term follow-up results of TELLOMAK Phase 2 trial in Sézary syndrome and mycosis fungoides
  • Trial in Progress poster on IPH4502, Innate's differentiated ADC in development in advanced solid tumors expressing Nectin-4
  • AstraZeneca to present a poster on updated results from the Phase 2 trial NeoCOAST-2 in resectable NSCLC